← Back to all trials
Recruiting
NCT05638620
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
Conditions: Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
Sex: All
Ages: 18 Years – 100 Years
Phase: PHASE1
Enrollment: 20
Sponsor: Jonathann Kuo, MD
Location: United States
Summary
The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.
Eligibility Criteria
Inclusion Criteria:Prior confirmed COVID-19 diagnosis by standard RT-PCR assay or equivalent testingPersistent symptoms that continue four or more weeks after the start of a COVID-19 infectionQuantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31).
The COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor.Quantified pain symptoms of pain interference or pain intensity as reported by the patient on the screener Patient-Reported Outcomes Measurement Information System (PROMIS-29)Exclusion Criteria:Under age 18Prior SGBAllergy to amide local anesthetics (e.g., ropivacaine, bupivacaine/Marcaine)PregnancyCurrent anticoagulant useHistory of a bleeding disorderHistory of glaucomaInfection or mass at injection siteFor the consistency of this study, patients who deny all autonomic symptoms on the COMPASS-31 or pain symptoms on the PROMIS-29 will also be excluded
Source: ClinicalTrials.gov (NCT05638620). StuddyBuddy aggregates publicly available trial information.
